| Title |
Management of thrombotic thrombocytopenic purpura: current perspectives
|
|---|---|
| Published in |
Journal of Blood Medicine, February 2014
|
| DOI | 10.2147/jbm.s46458 |
| Pubmed ID | |
| Authors |
Piers Blombery, Marie Scully |
| Abstract |
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy which causes significant morbidity and mortality unless promptly recognized and treated. The underlying pathogenesis of TTP is a severe deficiency in ADAMTS13 activity, a metalloprotease that cleaves ultralarge von Willebrand factor multimers. This deficiency is either autoantibody mediated (acquired TTP) or due to deleterious mutations in the gene encoding ADAMTS13 (congenital TTP). The elucidation of this disease mechanism has reinforced the rationale and place of current therapies (eg, plasma exchange) as well as providing a basis for the prospective evaluation of immunotherapy with rituximab in addition to classic immunosuppression (eg, corticosteroid) in autoantibody-mediated TTP. This review discusses the current evidence base for therapeutic interventions in acquired and congenital TTP as well as providing a practical approach to the other aspects of investigation and management for which a firm evidence base is lacking. Novel agents that are currently being evaluated in prospective trials and future directions of therapy are also discussed which are expected to make an important contribution to improving outcomes in patients with TTP. |
X Demographics
The data shown below were collected from the profiles of 11 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 3 | 27% |
| India | 3 | 27% |
| Tanzania, United Republic of | 1 | 9% |
| Unknown | 4 | 36% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 64% |
| Practitioners (doctors, other healthcare professionals) | 3 | 27% |
| Scientists | 1 | 9% |
Mendeley readers
The data shown below were compiled from readership statistics for 144 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | <1% |
| United States | 1 | <1% |
| Australia | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 140 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 15% |
| Student > Ph. D. Student | 20 | 14% |
| Other | 16 | 11% |
| Student > Postgraduate | 15 | 10% |
| Student > Master | 15 | 10% |
| Other | 33 | 23% |
| Unknown | 24 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 69 | 48% |
| Biochemistry, Genetics and Molecular Biology | 15 | 10% |
| Agricultural and Biological Sciences | 12 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Nursing and Health Professions | 3 | 2% |
| Other | 10 | 7% |
| Unknown | 27 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 101. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 January 2023.
All research outputs
#414,537
of 25,243,120 outputs
Outputs from Journal of Blood Medicine
#9
of 330 outputs
Outputs of similar age
#4,056
of 320,356 outputs
Outputs of similar age from Journal of Blood Medicine
#2
of 3 outputs
Altmetric has tracked 25,243,120 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 330 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 320,356 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.